ArticleBMJ open2023

Study protocol of a phase 2, randomised, placebo-controlled, double-blind, adaptive, parallel group clinical study to evaluate the efficacy and safety of recombinant alpha-1-microglobulin in subjects at high risk for acute kidney injury following open-chest cardiac surgery (AKITA trial).

C David Mazer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.